Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36059942)

  • 1. Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review.
    Zhang X; Han H; Zhao J; Liu X; Zhang J; Sun R; Li S; Liu B; Zhu H; Jiao S; Li X; Tang H
    Front Pharmacol; 2022; 13():964606. PubMed ID: 36059942
    [No Abstract]   [Full Text] [Related]  

  • 2. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
    Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
    Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.
    Chen X; Zha W; Su M; Meng N; Cao S; Niu B; Qi X
    Front Pharmacol; 2023; 14():1053805. PubMed ID: 36817153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced lung adenocarcinoma patient with
    Jia K; Yang S; Chen B; Yu J; Wu Y; Li W; Zhou F; Wu F; Feng G; Ren S
    Ann Transl Med; 2022 Mar; 10(6):386. PubMed ID: 35433998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
    Zhang SS; Ou SI
    Lung Cancer (Auckl); 2022; 13():67-73. PubMed ID: 36317157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 8. Osimertinib in uncommon
    Wang Y; Dorwal P; Rajadurai S; Arulananda S
    Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Lung Adenocarcinoma Patient With a Rare
    Wei Y; Cui Y; Guo Y; Li L; Zeng L
    Front Oncol; 2021; 11():700345. PubMed ID: 34178699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in
    Pan X; Shi M
    Heliyon; 2024 Mar; 10(5):e27106. PubMed ID: 38439894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer.
    Hu S; Ming H; He Q; Ding M; Ding H; Li C
    Front Oncol; 2024; 14():1314301. PubMed ID: 38651148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review.
    Chen T; Chen J; Liu DS; Shu YL; Fu MY; Gou HJ; Lei KJ; Jia YM
    Front Oncol; 2023; 13():1233198. PubMed ID: 37920163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
    BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI.
    Ding J; Ding X; Zeng J; Liu X
    Front Pharmacol; 2024; 15():1357913. PubMed ID: 38440180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.